ATE525085T1 - Behandlung von neoplasmen mit neurotoxin - Google Patents
Behandlung von neoplasmen mit neurotoxinInfo
- Publication number
- ATE525085T1 ATE525085T1 AT05814023T AT05814023T ATE525085T1 AT E525085 T1 ATE525085 T1 AT E525085T1 AT 05814023 T AT05814023 T AT 05814023T AT 05814023 T AT05814023 T AT 05814023T AT E525085 T1 ATE525085 T1 AT E525085T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer
- distant
- disease
- neurotoxin
- botulinum toxin
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 9
- 101710138657 Neurotoxin Proteins 0.000 title abstract 3
- 239000002581 neurotoxin Substances 0.000 title abstract 3
- 231100000618 neurotoxin Toxicity 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 abstract 6
- 108030001720 Bontoxilysin Proteins 0.000 abstract 3
- 229940053031 botulinum toxin Drugs 0.000 abstract 3
- 230000003612 virological effect Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 208000031888 Mycoses Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000004611 cancer cell death Effects 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 230000012010 growth Effects 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000036737 immune function Effects 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61244304P | 2004-09-23 | 2004-09-23 | |
| PCT/US2005/033982 WO2006034404A2 (en) | 2004-09-23 | 2005-09-23 | Treating neoplasms with neurotoxin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE525085T1 true ATE525085T1 (de) | 2011-10-15 |
Family
ID=36090674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05814023T ATE525085T1 (de) | 2004-09-23 | 2005-09-23 | Behandlung von neoplasmen mit neurotoxin |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US7709440B2 (de) |
| EP (4) | EP2298339B1 (de) |
| AT (1) | ATE525085T1 (de) |
| CA (2) | CA2586793C (de) |
| DK (2) | DK1802339T3 (de) |
| ES (3) | ES2555856T3 (de) |
| PT (2) | PT1802339E (de) |
| WO (1) | WO2006034404A2 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002000172A2 (en) * | 2000-06-28 | 2002-01-03 | Ira Sanders | Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| EP1863524A1 (de) * | 2005-03-03 | 2007-12-12 | Universite Catholique De Louvain | Verfahren und zusammensetzungen zur behandlung von krebs |
| US8105611B2 (en) * | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
| ES2599033T3 (es) * | 2008-11-26 | 2017-01-31 | Toxcure, Inc. | Tratamiento de neoplasias con neurotoxina |
| US10398668B2 (en) | 2010-10-19 | 2019-09-03 | The Board Of Regents Of The University Of Oklahoma | Glutamate treatment of cardiovascular disorders |
| US9744235B2 (en) | 2010-10-19 | 2017-08-29 | The Board Of Regents Of The University Of Oklahoma | Treatment of cardiovascular disorders with targeted nanoparticles |
| US8740872B2 (en) | 2010-10-19 | 2014-06-03 | The Board Of Regents Of The University Of Oklahoma | Magnetically-targeted treatment for cardiac disorders |
| EP2649985A1 (de) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Verbindungen zur Hemmung neuronaler Exozytose (III) |
| EP2649984A1 (de) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Verbindungen zur Hemmung neuronaler Exozytose |
| EP2649983A1 (de) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Verbindungen zur Hemmung neuronaler Exozytose (II) |
| AU2013246882B2 (en) | 2012-04-13 | 2017-10-19 | Lubrizol Advanced Materials, Inc. | Compounds which inhibit neuronal exocytosis (II) |
| US9473152B2 (en) * | 2013-11-08 | 2016-10-18 | Taiwan Semiconductor Manufacturing Company, Ltd. | Coupling structure for inductive device |
| EP4570203A3 (de) * | 2014-12-04 | 2025-08-13 | Autonomix Medical, Inc. | Systeme und verfahren zur regulierung von organ- und/oder tumorwachstumsraten, -funktion und/oder -entwicklung |
| WO2018039090A1 (en) * | 2016-08-20 | 2018-03-01 | Gregg John Maicolm Hall | Methods of use & compositions of ibd, ibs, & antineoplastic microbial therapeutics |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU683275B2 (en) * | 1993-06-10 | 1997-11-06 | Allergan, Inc. | Multiple botulinum toxins for treating neuromuscular disorders and conditions |
| US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
| US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
| US7838007B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating mammary gland disorders |
| US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
| US6641820B1 (en) | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
| US6464986B1 (en) | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
| US6565870B1 (en) | 2000-04-28 | 2003-05-20 | Allergan, Inc. | Methods for treating bone tumors |
| WO2002009743A1 (en) | 2000-08-02 | 2002-02-07 | Allergan Sales, Inc. | Method for treating a neoplasm |
| US20060134140A1 (en) * | 2001-04-12 | 2006-06-22 | Dana Lasko | Compositions and methods for treating tumor spreading |
| DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
| EP1599213A4 (de) | 2003-02-24 | 2009-07-15 | Ira Sanders | Zellmembran-translokation von regulierten snare- inhibitoren, zusammensetzungen dafür und verfahren zur behandlung von erkrankungen |
| US8071550B2 (en) | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
| US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
| US8048423B2 (en) * | 2003-12-09 | 2011-11-01 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
| RU2346996C2 (ru) | 2004-06-29 | 2009-02-20 | ЮРОПИЭН НИКЕЛЬ ПиЭлСи | Усовершенствованное выщелачивание основных металлов |
| US8343929B2 (en) | 2004-09-23 | 2013-01-01 | Toxcure, Inc. | Treating neoplasms with neurotoxin |
| EP1863524A1 (de) | 2005-03-03 | 2007-12-12 | Universite Catholique De Louvain | Verfahren und zusammensetzungen zur behandlung von krebs |
| US8105611B2 (en) | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
-
2005
- 2005-09-23 DK DK05814023.7T patent/DK1802339T3/da active
- 2005-09-23 EP EP10012869.3A patent/EP2298339B1/de not_active Expired - Lifetime
- 2005-09-23 EP EP15002090.7A patent/EP2985034A1/de not_active Withdrawn
- 2005-09-23 US US11/577,838 patent/US7709440B2/en not_active Expired - Fee Related
- 2005-09-23 ES ES10012869.3T patent/ES2555856T3/es not_active Expired - Lifetime
- 2005-09-23 ES ES10000417.5T patent/ES2548152T3/es not_active Expired - Lifetime
- 2005-09-23 EP EP05814023A patent/EP1802339B1/de not_active Expired - Lifetime
- 2005-09-23 ES ES05814023T patent/ES2373963T3/es not_active Expired - Lifetime
- 2005-09-23 CA CA2586793A patent/CA2586793C/en not_active Expired - Fee Related
- 2005-09-23 WO PCT/US2005/033982 patent/WO2006034404A2/en not_active Ceased
- 2005-09-23 DK DK10000417.5T patent/DK2168594T3/en active
- 2005-09-23 EP EP20100000417 patent/EP2168594B1/de not_active Expired - Lifetime
- 2005-09-23 PT PT05814023T patent/PT1802339E/pt unknown
- 2005-09-23 AT AT05814023T patent/ATE525085T1/de active
- 2005-09-23 CA CA2875562A patent/CA2875562A1/en not_active Abandoned
- 2005-09-23 PT PT100004175T patent/PT2168594E/pt unknown
-
2010
- 2010-03-17 US US12/725,955 patent/US8435951B2/en not_active Expired - Fee Related
-
2013
- 2013-05-02 US US13/875,542 patent/US20130236497A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8435951B2 (en) | 2013-05-07 |
| CA2875562A1 (en) | 2006-03-30 |
| ES2555856T3 (es) | 2016-01-11 |
| US7709440B2 (en) | 2010-05-04 |
| EP2298339B1 (de) | 2015-07-15 |
| PT1802339E (pt) | 2011-12-15 |
| DK1802339T3 (da) | 2011-10-24 |
| EP1802339B1 (de) | 2011-09-21 |
| EP2985034A1 (de) | 2016-02-17 |
| DK2168594T3 (en) | 2015-08-03 |
| WO2006034404A2 (en) | 2006-03-30 |
| CA2586793A1 (en) | 2006-03-30 |
| PT2168594E (pt) | 2015-09-15 |
| EP2168594A1 (de) | 2010-03-31 |
| EP1802339A2 (de) | 2007-07-04 |
| US20090028972A1 (en) | 2009-01-29 |
| ES2373963T3 (es) | 2012-02-10 |
| EP2298339A1 (de) | 2011-03-23 |
| ES2548152T3 (es) | 2015-10-14 |
| US20130236497A1 (en) | 2013-09-12 |
| WO2006034404A3 (en) | 2006-08-10 |
| EP2168594B1 (de) | 2015-04-29 |
| US20100209456A1 (en) | 2010-08-19 |
| CA2586793C (en) | 2015-03-24 |
| EP1802339A4 (de) | 2008-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE525085T1 (de) | Behandlung von neoplasmen mit neurotoxin | |
| DE60231439D1 (de) | Mitotische kinesinhemmer | |
| DE60234278D1 (de) | Mitotische kinesin-hemmer | |
| EA200900272A1 (ru) | Комбинации для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом | |
| DE60329756D1 (de) | Mitotische kinesin-hemmer | |
| ATE372341T1 (de) | Inhibitoren von mitotischem kinesin | |
| DE602004032446D1 (de) | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel | |
| MY194058A (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
| EA202191257A1 (ru) | Противораковая терапия на основе иммуноцитов, связывающих liv1 | |
| MXPA03002576A (es) | Metodos para tratar lesiones musculares. | |
| DE60329990D1 (de) | Mitotische kinesin-hemmer | |
| ATE443724T1 (de) | Antikrebs-antikörper mit reduzierter komplementfixierung | |
| TR199701669A1 (xx) | Deri preparasyonu i�in bile�imler. | |
| MXPA05007821A (es) | Terapia de combinacion para tratar deficiencias de proteinas. | |
| MX2021011824A (es) | Composiciones, dispositivos y metodos para la terapia del factor vii. | |
| GB0308952D0 (en) | Method | |
| DE69738887D1 (de) | Tumor necrosis factor rezeptor abspaltendes enzym, dessen zubereitungen und verwendungen | |
| EA200500871A1 (ru) | Пептиды, ингибирующие ангиогенез, миграцию клеток, инвазию клеток и пролиферацию клеток, композиции и их применение | |
| ATE375786T1 (de) | Chitin-mikropartikel und ihre medizinische verwendung | |
| ATE543502T1 (de) | Allomon-abstossungsmittel zur kontrolle von arachnidae | |
| NO20053947L (no) | Forbedrede antitumorale behandlinger. | |
| ATE392210T1 (de) | Methoden zur behandlung von festen tumoren und metastasen mit gentherapie | |
| DK1383516T3 (da) | Indgivelse af et polysaccharid samtidig med et kemoterapeutisk middel til behandling af cancer | |
| PA8506201A1 (es) | Quimioterapia de combinacion (combination chemotherapy) | |
| ATE243522T1 (de) | Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1802339 Country of ref document: EP |